- Boceprevir. NS3 protease inhibitor, Treatment of chronic hepatitis C
[作者：Campas, C; Pandian, R; Bolos, J; Castaner, R,期刊：Drugs of the Future, 页码：697-707 , 文章类型： Article，,卷期：2009年34-9]
- Boceprevir (SCH-503034) is a potent, orally bioavailable inhibitor of the hepatitis C virus (HCV) NS3 protease. Several studies hove demonstrated that boceprevir is well tolerated when given in combination with peginterf...
- Proteosome Inhibitor Oncolytic
[作者：Davies, S; Pandian, R; Bolos, J; Castaner, R,期刊：Drugs of the Future, 页码：708-716 , 文章类型： Article，,卷期：2009年34-9]
- Proteosome inhibitors ore a new class of drugs that hove been shown to be cytotoxic and to induce apoptosis in tumor cells, particularly multiple myelomo (MM). In a bid to overcome the dose-limiting toxicity and adverse ...
- ADVANCES IN SYSTEMIC siRNA DELIVERY
[作者：Leng, Q; Woodle, MC; Lu, PY; Mixson, AJ,期刊：Drugs of the Future, 页码：721-737 , 文章类型： Review，,卷期：2009年34-9]
- Sequence-specific gene silencing with small interfering RNA (SiRNA) has transformed basic science research, and the efficacy of siRNA therapeutics in a variety of diseases is now being evaluated in preclinical and clinic...
- CURRENT CONCEPTS IN THE TREATMENT OF ADAMANTIADES-BEHCET'S DISEASE
[作者：Bonitsis, NG; Altenburg, A; Krause, L; Stache, T; Zouboulis, CC,期刊：Drugs of the Future, 页码：749-763 , 文章类型： Review，,卷期：2009年34-9]
- Adamantiades-Behcet's disease is a systemic vascular reaction/vasculitis of unknown etiology, which is characterized by periodically recurrent oral aphthous ulcers; genital ulcers, ocular inflammation that con be sigh t-...
- THERAPEUTIC TARGETS FOR SEPSIS
[作者：Sorbera, L; Dulsat, C; Rosa, E,期刊：Drugs of the Future, 页码：765-770 , 文章类型： Article，,卷期：2009年34-9]
- Sepsis is the initial systemic inflammatory response syndrome (SIRS) associated with a confirmed infectious process. It is a spectrum of clinical conditions caused by the immune response of a host to severe infection (e....
|